Preventing brain side effects during car t-cell therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether giving a drug called natalizumab before CAR T-cell therapy can lower the risk of a serious side effect that affects the brain and nervous system (called ICANS). It is for people with diffuse large B-cell lymphoma or mantle cell lymphoma that has come back or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have diffuse large B-cell lymphoma or mantle cell lymphoma that has returned or not responded to treatment.
- You are already eligible to receive a standard CAR T-cell therapy (either axicabtagene ciloleucel or brexucabtagene autoleucel) at your treatment center.
- You are in reasonably good health, able to care for yourself, and do not have certain serious infections or brain conditions.
- If you or your partner can become pregnant, you must agree to use two effective birth control methods during the study and for a period after treatment (12 months for women, 4 months for men).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give treatment directly into the spinal fluid for a serious side effect of CAR T cell therapy called ICANS. It may help people with certain types of lymphoma who are getting standard CAR T therapy and experience this brain-related complication.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
This trial tests if a spinal injection of three common chemotherapy drugs can reduce or prevent serious brain and nerve side effects in people receiving CAR-T cell therapy for cancer.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.